Lack of adjuvanticity of human recombinant interleukin-1 beta in collagen induced arthritis in rats.
We investigated the influence of human recombinant interleukin-1 beta (hrIL-1 beta) on the time-course of collagen induced arthritis (CIA) when injected concomitantly with the arthritogenic emulsion. Three sensitizing procedures were compared. The control group received type II collagen only. The other groups differed by the adjunction of demonstrated (MDP) or potential (IL-1 beta) adjuvant. No adjuvant effect of IL-1 was observed as judged on clinical or radiological scores. On the contrary, MDP significantly worsened the lesions of the injected right hindpaw, and increased the incidence of CIA. Surprisingly, humoral response to type II collagen was decreased in the group receiving IL-1 beta. This might be explained by a non specific increase of antigen clearance.
Fener
P
P
Laboratoire de Pharmacologie et Clinique Rhumatologique, URA CNRS 1288, Faculté de Médecine, Vandoeuvre-les-Nancy.
Gillet
P
P
Charrière
G
G
Bannwarth
B
B
Drelon
E
E
Jouzeau
J Y
JY
Chevrier
D
D
Terlain
B
B
Pourel
J
J
Hartmann
D J
DJ
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology; D000818:Animals; D001169:Arthritis, Experimental / Q000000981:diagnostic imaging / Q000473:pathology*; D003094:Collagen; D005260:Female; D005528:Foot / Q000473:pathology; D007375:Interleukin-1 / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D011859:Radiography; D051381:Rats; D011920:Rats, Inbred WF
D007375:Interleukin-1; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D003094:Collagen